Assetmark Inc. Acquires 99,575 Shares of Healthpeak Properties, Inc. $DOC

Assetmark Inc. grew its holdings in shares of Healthpeak Properties, Inc. (NYSE:DOC) by 23.0% in the 1st quarter, HoldingsChannel reports. The firm owned 532,371 shares of the real estate investment trust’s stock after acquiring an additional 99,575 shares during the quarter. Assetmark Inc.’s holdings in Healthpeak Properties were worth $8,747,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. Fiduciary Trust Co boosted its holdings in shares of Healthpeak Properties by 4.9% in the 3rd quarter. Fiduciary Trust Co now owns 13,807 shares of the real estate investment trust’s stock worth $264,000 after buying an additional 644 shares during the last quarter. Patton Fund Management Inc. increased its holdings in Healthpeak Properties by 5.2% during the fourth quarter. Patton Fund Management Inc. now owns 13,002 shares of the real estate investment trust’s stock worth $209,000 after buying an additional 648 shares during the last quarter. Quadrant Capital Group LLC raised its position in Healthpeak Properties by 1.9% in the third quarter. Quadrant Capital Group LLC now owns 37,650 shares of the real estate investment trust’s stock worth $721,000 after acquiring an additional 718 shares during the period. Quantum Portfolio Management LLC raised its position in Healthpeak Properties by 2.5% in the first quarter. Quantum Portfolio Management LLC now owns 29,372 shares of the real estate investment trust’s stock worth $483,000 after acquiring an additional 728 shares during the period. Finally, Intrua Financial LLC boosted its stake in Healthpeak Properties by 1.1% in the first quarter. Intrua Financial LLC now owns 66,702 shares of the real estate investment trust’s stock valued at $1,096,000 after acquiring an additional 744 shares during the last quarter. 93.57% of the stock is currently owned by institutional investors.

Healthpeak Properties Price Performance

DOC stock opened at $22.27 on Tuesday. The firm has a 50 day moving average of $20.52 and a 200-day moving average of $18.30. The firm has a market capitalization of $15.36 billion, a P/E ratio of 69.61, a price-to-earnings-growth ratio of 3.50 and a beta of 1.02. Healthpeak Properties, Inc. has a 12 month low of $15.70 and a 12 month high of $22.72. The company has a current ratio of 2.96, a quick ratio of 2.96 and a debt-to-equity ratio of 1.15.

Healthpeak Properties (NYSE:DOC) last posted its earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. The business had revenue of $752.95 million for the quarter, compared to analysts’ expectations of $694.59 million. During the same period in the prior year, the company posted $0.46 EPS. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. As a group, sell-side analysts predict that Healthpeak Properties, Inc. will post 1.75 earnings per share for the current fiscal year.

Healthpeak Properties Dividend Announcement

The firm also recently disclosed a monthly dividend, which will be paid on Friday, September 25th. Investors of record on Monday, September 14th will be paid a dividend of $0.1017 per share. The ex-dividend date of this dividend is Monday, September 14th. This represents a c) annualized dividend and a yield of 5.5%. Healthpeak Properties’s dividend payout ratio (DPR) is currently 381.25%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Evercore downgraded shares of Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 target price for the company. in a research report on Monday, May 11th. Scotiabank increased their price objective on Healthpeak Properties from $19.00 to $21.00 and gave the company a “sector perform” rating in a report on Wednesday, May 27th. Wells Fargo & Company raised their target price on Healthpeak Properties from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded Healthpeak Properties from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Finally, JPMorgan Chase & Co. upped their price target on Healthpeak Properties from $18.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Four research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.62.

Insider Transactions at Healthpeak Properties

In related news, insider Scott R. Bohn sold 10,989 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the transaction, the insider directly owned 7,636 shares in the company, valued at $148,520.20. The trade was a 59.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.23% of the company’s stock.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.